Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

LA JOLLA, Calif., Nov. 14 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced financial results for the third quarter ended September 30, 2007. For the three-month period, the Company posted revenue of $2.5 million and a net loss of $6.8 million. Cash and cash equivalents totaled $39.7 million at September 30, 2007.

"Last quarter we continued to advance our three priority product candidates and most notably, after the quarter ended, we announced positive results from our Phase IIb clinical trial evaluating our lead compound, tezampanel, in acute migraine," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "We now have two migraine studies in which tezampanel demonstrated statistically significant improvement on the primary end point of pain response at two hours post-dose compared to placebo. These Phase IIb results further establish the efficacy and safety of tezampanel and we are pleased to be advancing tezampanel into later-stage clinical development."

Highlights:

-- In October 2007, announced that tezampanel met the primary endpoint at

the 40 mg dose in a 306-patient, Phase IIb clinical trial for the

treatment of a single, acute migraine attack. Two other doses, 70 mg

and 100 mg, were evaluated and also demonstrated effects across a

number of pain measurements although neither dose reached statistical

significance on the primary endpoint. In this trial, tezampanel was

well-tolerated and there were no serious or medically important

adverse events reported.

-- Initiated a Phase I multiple-dose clinical trial of tezampanel to

evaluate the safety, tolerability
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 04, 2015 Follow us on ... of the fastest growing technologies in the life sciences ... visualization is driving growth in nucleic acid detection technologies ... of gene expressions will continue to benefit the qPCR ... fields ranging from pharma, biotech, food & beverage to ...
(Date:3/4/2015)... , March 4, 2015 ... Paris en décembre 2011, ... SARAH   », qui compare   l ... le   sorafénib dans le carcinome hépatocellulaire avancé, ... cancer du foie avancé   ; les résultats ...
(Date:3/3/2015)... DIEGO and TORONTO, March 3, 2015 /PRNewswire/ - Aptose ... developing new therapeutics and molecular diagnostics that target the ... the quarter and seventh-month period ended December 31, 2014. ... its fiscal year end from May 31 to December ... we are reporting today are for the quarter and ...
(Date:3/3/2015)... , March 3, 2015 NASA astronaut Scott ... this month to spend a year living and working on ... interviews from 5:30 to 7 a.m. EDT Monday, March 9. ... as he completes the final weeks of his training. ... video on NASA Television highlighting his mission training and previous ...
Breaking Biology Technology:Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 2Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 3Focus on Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR Instrumentation Market, According to a New Report by Global Industry Analysts, Inc. 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 2Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 3Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 4Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 5Traitement du cancer primitif du foie : Recrutement terminé pour l'étude SARAH et résultats attendus fin 2016 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12NASA Astronaut Scott Kelly Available for Interviews before One-Year Space Station Mission 2
... YORK, October 25 XTL Biopharmaceuticals,Ltd. (NASDAQ: ... has,entered into definitive agreements with institutional investors relating ... million in gross proceeds of,ordinary shares, represented by ... transaction are Perceptive Life Sciences Fund, Quogue,Capital LLC, ...
... Innovative Fall Detection ... and Prevention System, FALLS CHURCH, ... in the elderly. The National Institute on Aging (NIA),part of the ... Business Innovation Research grant entitled,"Non-Intrusive Locomotion and Gait Stability Analysis Monitoring ...
... October 25 Glycominds Ltd., a,bio-diagnostics company specializing ... autoimmune diseases and cancer, announced today,entering into a ... an,NCI designated cancer center to develop a new ... very pleased to work with FCCC on this ...
Cached Biology Technology:XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 2XTL Biopharmaceuticals Ltd. Announces $9.6 Million Private Placement to Institutional Investors 3Leading Edge Research Underway in Fall Prevention for Seniors 2Leading Edge Research Underway in Fall Prevention for Seniors 3Glycominds and Fox Chase Cancer Center Announce a Collaboration to Discover New Cancer Detection Diagnostic Tests 2
(Date:2/5/2015)... Jan. 28, 2015 Research and Markets ... of the "Global Biometrics Market (2014-2020): Market ... Countries " report to their offering. , ... Asia-Pacific is anticipated to overtake ... to increasing government spending towards IT security, government ...
(Date:1/22/2015)... , Jan. 9, 2015 Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ... in general the State of Washington,s ... a new enrollment and central issuance system for driver,s licenses ... The project planning and development will start in January ...
(Date:1/22/2015)... Wis. , Jan. 15, 2015  BellBrook Labs, ... drug discovery, announced the launch of a TR-FRET ... the company,s Transcreener UDP Assay, a high throughput ... The new assay will allow for sensitive detection ...
Breaking Biology News(10 mins):Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 2Global Biometrics Market (2014-2020): Market Forecast By Technologies, Applications, End Use, Regions and Countries 3Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2
... supermarket headlines tell us so., Inquiring Texas research minds ... tiny, sometimes obscure pest that can damage plants during ... cotton for about four weeks," said Dr. Megha Parajulee, ... feed on new plant growth, primarily the first small ...
... ago, "ultraconserved elements" were discovered in the genomes of mice, ... in length or longer -- some are over 700 base ... three species. They have been perfectly conserved since the last ... 85 million years ago. These and other highly ...
... cells could take a mix of enzyme ingredients, blend ... elaborate chemical structure such as penicillin. Researchers at UC ... of Pharmacy and Pharmaceutical Sciences and the University of ... to mimic this process outside of a cell. ...
Cached Biology News:Inquiring minds want to know about cotton fleahoppers 2Inquiring minds want to know about cotton fleahoppers 3Ultraconserved elements in the genome: Are they indispensable? 2Ultraconserved elements in the genome: Are they indispensable? 3Ultraconserved elements in the genome: Are they indispensable? 4Researchers develop simple method to create natural drug products 2
... Gelzyme is an agarose-digesting enzyme ... cleaves simple carbohydrate bonds in agarose ... longer gel. The remaining carbohydrate molecules ... manipulation. DNA isolated with Gelzyme enzyme ...
...
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
... 0 (or Cap 0-like) RNA into Cap ... been shown to increase in vivo translation ... is seen in Cap 0 structures created ... well as those Cap 0 structures created ...
Biology Products: